Citations

Showing 10 of 108083 citations.

Outcomes of Returning Medically Actionable Genomic Results in Pediatric Research
Blumling, Amy A. , Prows, Cynthia A. , Chung, Wendy K. , Clayton, Ellen Wright , Holm, Ingrid A. , Wiesner, Georgia L. , Connolly, John J. , Harley, John B. , Håkonarson, Håkon , McGowan, Michelle L. , Miller, Erin M. , Myers, Melanie F. , Chung, Wendy K. , Clayton, Ellen Wright , Holm, Ingrid A , Connolly, John J , Hakonarson, Hakon , Myers, Melanie F , Harr, Margaret

Mayo Clinic

Journal of Personalized Medicine | November 16, 2022 | Volume: 12 | Issue: 11 | Pages: 1910

10.3390/jpm12111910 | PMID 36422086 Get It

Purpose: The electronic Medical Records and Genomics (eMERGE) Phase III study was undertaken to assess clinical utility of returning medically actionable genomic screening results. We assessed pediatric clinical outcomes following return of pathogenic/likely pathogenic (P/LP) variants in autosomal dominant conditions with available effective interventions. Methods: The two eMERGE III pediatric sites collected outcome data and assessed changes in medical management at 6 and 12 months. Results: We returned P/LP results to 29 participants with outcome data. For 23 of the 29 participants, the P/LP results were previously unknown. Five of the 23 participants were already followed for conditions related to the P/LP variant. Of those receiving novel results and not being followed for the condition related to the P/LP result (n = 18), 14 (77.8%) had a change in healthcare after return of results (RoR). Following RoR, cascade testing of family members occurred for 10 of 23 (43.5%). Conclusions: The most common outcomes post-RoR included imaging/laboratory testing and health behavior recommendations. A change in healthcare was documented in 77.8% of those receiving results by 6 months. Our findings demonstrate how return of genomic screening results impacts healthcare in pediatric populations.
Point/Counterpoint: Should patients be presented before entering the room during ward rounds?
Centor, Robert M. , Goldszmidt, Mark , Heudebert, Gustavo R., Heudebert, Alonso, Willett, Lisa L., Ratelle, John T. , Willett, Lisa L.

Mayo Clinic

Journal of Hospital Medicine | November 16, 2022 | Volume: 18 | Issue: 2 | Pages: 188-192

10.1002/jhm.13003 | PMID 36380660 Get It

Evolutions in Clinical Chemistry
Baudhuin, Linnea M. , Park, Jason Y. , Young, Ian Stuart

Mayo Clinic

Clinical Chemistry | November 15, 2022 | Volume: 69 | Issue: 1 | Pages: 1-2

10.1093/clinchem/hvac184 | PMID 36598548 Get It

An Immunocompromised Adult With Oral Ulcers
Gawey, Brent J. , Gopalsamy, Srinivasa Nithin , Kalapila, Aley G., Gawey, Brent

Mayo Clinic

Annals of Internal Medicine: Clinical Cases | November 15, 2022 | Volume: 1 | Issue: 9 | Pages: No page available

10.7326/aimcc.2022.0643 Get It

Lifetime Management of Aortic Stenosis: Transcatheter Versus Surgical Treatment for Young and Low-Risk Patients
Russo, Giulio , Tang, Gilbert H.L. , Sangiorgi, Giuseppe , Enriquez‐Sarano, Maurice , Maisano, Francesco , Pedicino, Daniela , Enriquez-Sarano, Maurice , Russo, Giulio , Maisano, Francesco , Taramasso, Maurizio

Mayo Clinic

Circulation: Cardiovascular Interventions | November 15, 2022 | Volume: 15 | Issue: 11 | Pages: 915-927

10.1161/circinterventions.122.012388 | PMID 36378737 Get It

Transcatheter aortic valve replacement is now indicated across all risk categories of patients with symptomatic severe aortic stenosis and has been proposed as first line option for the majority of patients >74 years old. However, median age of patients enrolled in the transcatheter aortic valve replacement low-risk trials is 74 years and transcatheter aortic valve replacement has never been systematically investigated in young low risk patients. Although the long-term data in surgical aortic valve replacement in young patients (age <75) are well known, such data remain lacking in transcatheter aortic valve replacement. In the absence of clear guideline recommendations in patients with challenging anatomies (eg, hostile calcium, bicuspid), it is important to know the potential advantages and disadvantages of each treatment and to consider how they might integrate with each other in the lifetime management of such patients. In this review, we discuss current outstanding issues on the management of severe aortic stenosis from a lifetime management perspective, particularly in terms of initial intervention and future reinterventions.
Chylous Ascites: Reassessment of Diagnostic Criteria in Patients With Portal Hypertension
Matchett, Caroline L. , McConnell, Joseph P., Simonetto, Douglas A. , Kamath, Patrick S. , Rattan, Puru , Donato, Leslie J. , Simonetto, Douglas A

Mayo Clinic

American Journal of Gastroenterology | November 15, 2022 | Volume: 118 | Issue: 2 | Pages: 364-366

10.14309/ajg.0000000000002072 | PMID 36379155 Get It

INTRODUCTION: The triglyceride (TG) threshold for diagnosis of chylous ascites in patients with portal hypertension remains uncertain. METHODS: Retrospective analysis of lipoprotein electrophoresis was conducted in 286 consecutive ascites samples. RESULTS: Ascitic TG ≥ 81 mg/dL is 95.4% sensitive and 94.6% specific for chylous ascites diagnosed by the presence of significant chylomicron population. DISCUSSION: The cutoff for chylous ascites diagnosis should be TG ≥ 81 mg/dL.
Crushed vs dissolved bictegravir/emtricitabine/tenofovir alafenamide
Johnson, Tanner M , Rivera, Christina G. , Rivera, Christina G , Johnson, Tanner M

Mayo Clinic

American Journal of Health-System Pharmacy | November 15, 2022 | Volume: 80 | Issue: 4 | Pages: 180-181

10.1093/ajhp/zxac346 | PMID 36377971 Get It

BRUIN MCL-321: Phase III Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in BTK Inhibitor Naive Mantle Cell Lymphoma
Eyre, Toby A. , Shah, Nirav N. , Dreyling, Martin , Jurczak, Wojciech , Gandhi, Mitul, Chay, Christopher H., Sharman, Jeff P. , Andorsky, David , Messersmith, Hannah M, Ruppert, Amy S. , Muthig, Valerie A., Ito, Rodrigo, Wang, Michael , Jurczak, Wojciech , Wang, Yucai , Cheah, Chan Y. , Song, Yuqin , Muthig, Valerie

Mayo Clinic

Future Oncology | November 15, 2022 | Volume: 18 | Issue: 36 | Pages: 3961-3969

10.2217/fon-2022-0976 | PMID 36377973 Get It

Antibody Drug Conjugates in Lung Cancer
Merle, Geoffrey, Friedlaender, Alex , Desai, Aakash , Desai, Aakash P , Addeo, Alfredo

Mayo Clinic

The Cancer Journal | November 15, 2022 | Volume: 28 | Issue: 6 | Pages: 429-435

10.1097/ppo.0000000000000630 | PMID 36383905 Get It

Abstract An antibody-drug conjugate (ADC) comprises a monoclonal antibody that is specific to a tumor cell protein, bound to a cytotoxic agent, known as the payload. The use of ADCs is already common practice in several cancers, thanks to their efficacy and potentially more manageable toxicity profile, resulting from the release of the cytostatic payload directly in the tumors. Currently, early-phase trials of ADCs in non–small cell lung cancer are rapidly gaining ground, with promising results targeting HER2 (human epidermal growth factor 2), HER3, TROP2 (trophoblast cell surface antigen 2), MET, CEACAM5 (carcinoembryonic antigen–related cell adhesion molecule 5), and PTK7 (tyrosine protein kinase–like 7). Unfortunately, in small cell lung cancer, trials targeting the ubiquitous DLL3 (delta-like ligand 3) protein have failed to show clinically relevant results, despite significant toxicity.
Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH
Zhao, Xue-Qiao , Hippe, Daniel S. , Isquith, Daniel , Cantón, Gádor , Yamada, Kiyofumi , Balu, Niranjan , Crouse, John R., Anderson, Todd J. , Huston, John , O’Brien, Kevin D. , Yuan, Chun , Investigators, for the AIM-HIGH Carotid MRI Substudy, Huston, John , Hippe, Daniel S , Yamada, Kiyofumi , O'Brien, Kevin D , Hatsukami, Thomas S , Yuan, Chun , Sun, Jie , Investigators, for the AIM-HIGH Carotid MRI Substudy

Mayo Clinic

Circulation: Cardiovascular Imaging | November 15, 2022 | Volume: 15 | Issue: 11 | Pages: No page available

10.1161/circimaging.122.014229 | PMID 36378778 Get It

Background: Intraplaque hemorrhage (IPH) is associated with plaque progression and ischemic events, and plaque lipid content (% lipid core) predicts the residual atherosclerotic cardiovascular disease risk. This study examined the impact of IPH on lipid content change in the setting of intensive lipid-lowering therapy. Methods: In total, 214 AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low High-Density Lipoprotein/High Triglycerides: Impact on Global Health Outcomes) participants with clinically established ASCVD and low high-density lipoprotein cholesterol received cartoid MRI at baseline and 2 years to assess changes in carotid morphology and composition. Patients were randomized to extended-release niacin or placebo, and all received simvastatin with optional ezetimibe as necessary to lower low-density lipoprotein cholesterol to 40 to 80 mg/dL. Changes in lipid content and carotid morphology were tested using the Wilcoxon signed-rank test. Differences between subjects with and without IPH and between subjects assigned extended-release niacin or placebo were tested using the Wilcoxon rank-sum test. Linear regression was used to test the association of IPH and lipid content changes after adjusting for clinical risk factors. Results: Among 156 patients (61±9 years; 81% men) with complete MRI, prior statin use: <1 year, 26%; 1 to 5 years, 37%; >5 years, 37%. Triglycerides and ApoB decreased significantly, whereas high-density lipoprotein cholesterol and ApoA1 increased significantly over time. Plaque lipid content was significantly reduced (−0.5±2.4 %/year, P = 0.017) without a significant difference between the 2 treatment groups. However, the lipid content increased in plaques with IPH but regressed in plaques without IPH (1.2±2.5 %/year versus −1.0±2.2, P = 0.006). Additionally, IPH was associated with a decrease in lumen area (−0.4±0.9 mm2/year versus 0.3±1.4, P = 0.033). IPH remained significantly associated with increase in lipid content in multivariable analysis (54.4%, 95% CI: 26.8, 88.0, P < 0.001). Conclusions: Carotid plaques under continued intensive lipid-lowering therapy moved toward stabilization. However, plaques with IPH showed greater increases in lipid content and greater decreases in lumen area than plaques without IPH. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01178320.